Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme

Inclusion Criteria: * Age \>18 years of age * First recurrence of GBM (WHO Grade IV glioma or astrocytoma) in surgically accessible areas with prior histologic diagnosis of GBM * No known contraindications to receiving Avastin * Karnofsky Performance Status (KPS) of \> 70% * Radiation Therapy (RT) with ≥ 45 Gy tumor dose, completed ≥ 8 weeks prior to study entry Exclusion Criteria: * Contrast-enhancing tumor component crossing the midline, multi-focal tumor, or tumor dissemination (subependymal or leptomeningeal) * Clinically significant increased intracranial pressure (e.g., impending herniation), uncontrolled seizures, or requirement for immediate palliative treatment * Pregnant or need to breast feed during the study period (Negative beta-human chorionic gonadotropin (HCG) test required), or unable to maintain use of contraception while on study * Active infection requiring treatment or an unexplained febrile (\> 101.5 degrees F) illness * Known immunosuppressive disease, autoimmune disease or human immunodeficiency virus infection, Hepatitis B or Hepatitis C * Unstable or severe intercurrent medical conditions such as severe heart (New York Association Class 3 or 4) or lung (FEV1 \< 50%) disease, uncontrolled diabetes mellitus * Prior brachytherapy, carmustine wafer therapy, radiolabeled monoclonal antibodies, or stereotactic radiosurgery * Prior inguinal lymph node dissection Avastin-Specific Exclusion Criteria Subjects meeting any of the following criteria are ineligible for study entry: * Inadequately controlled hypertension (defined as systolic blood pressure \>150 mmHg and/or diastolic blood pressure \> 100 mmHg) * Prior history of hypertensive crisis or hypertensive encephalopathy * New York Heart Association (NYHA) Grade II or greater congestive heart failure * History of myocardial infarction or unstable angina within 6 months prior to enrollment * History of stroke or transient ischemic attack within 6 months prior to enrollment * Significant vascular disease (e.g. aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) (within 6 months prior to enrollment) * History of hemoptysis (\> or = 1/2 teaspoon of bright red blood per episode) within 28 days prior to enrollment * Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation) * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment * Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to enrollment * Serious, non-healing wound, active ulcer or untreated bone fracture * Proteinuria as defined by \> +1 on urinalysis dipstick * Known hypersensitivity to any component of Avastin * Pregnant (positive pregnancy test) or lactation